Genomes and Genes
Summary: Drugs that bind to and activate dopamine receptors.
Publications305 found, 100 shown here
- Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administrationRoshan Cools
Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
J Neurosci 29:1538-43. 2009..These data demonstrate that the effects of D(2) receptor stimulation on reversal learning in humans depend on task demands and baseline striatal dopamine synthesis capacity...
- Dopamine agonists and risk: impulse control disorders in Parkinson's diseaseValerie Voon
Behavioural and Clinical Neurosciences Institute, Department of Experimental Psychology, Downing Site, University of Cambridge, Cambridge CB2 3EB, UK
Brain 134:1438-46. 2011..taking task while performing functional magnetic resonance imaging, we investigated the relationship between dopamine agonists and risk taking in patients with Parkinson's disease with and without impulse control disorders...
- A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidolMichael J Frank
Department of Psychology and Program in NeuroscienceUniversity of Arizona, Tucson, AZ 85721, USA
Behav Neurosci 120:497-517. 2006..Drug effects interacted with baseline working memory span in all tasks. Taken together, the results support a unified account of the role of dopamine in modulating cognitive processes that depend on the basal ganglia...
- The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disordersP Sokoloff
INSERM, Unité de Neurobiologie et Pharmacologie, Moléculaire U573, Centre Paul Broca, 2ter rue d Alesia, 75014 Paris, France
CNS Neurol Disord Drug Targets 5:25-43. 2006..These data allow us to propose novel treatment options in PD, schizophrenia and drug addiction, which are awaiting evaluation in clinical trials...
- Association of dopamine agonist use with impulse control disorders in Parkinson diseaseDaniel Weintraub
Department of Psychiatry, University of Pennsylvania, and Parkinson s Disease Research, Education, and Clinical Center, USA
Arch Neurol 63:969-73. 2006..To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD)...
- Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patientsNikoletta Bodi
Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
Brain 132:2385-95. 2009..The never-medicated patients were also re-evaluated after 12 weeks of treatment with dopamine agonists. Reward and punishment processing was assessed by a feedback-based probabilistic classification task...
- Advances in the treatment of prolactinomasMary P Gillam
Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
Endocr Rev 27:485-534. 2006..Medical therapy with dopamine agonists is highly effective in the majority of cases and represents the mainstay of therapy...
- A reassessment of risks and benefits of dopamine agonists in Parkinson's diseaseAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Lancet Neurol 8:929-37. 2009..Among the first options are the dopamine agonists, which are commonly used both as an early monotherapy and as an adjunct therapy to levodopa...
- Punding in Parkinson's disease: its relation to the dopamine dysregulation syndromeAndrew H Evans
Reta Lila Weston Institute of Neurological Studies, London, United Kingdom
Mov Disord 19:397-405. 2004..We believe that this is an underreported, socially disabling phenomenon that is commonly associated with the syndrome of dopamine dysregulation and is phenomenologically distinct from both obsessive-compulsive disorder and mania...
- In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic miceEugenii A Rabiner
GlaxoSmithKline Clinical Imaging Centre, Hammersmith Hospital, London, UK
Synapse 63:782-93. 2009..The midbrain is thus an excellent target region to examine D3 receptor occupancy with [(11)C]-(+)-PHNO PET in vivo...
- Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysisEvelien D M Rooke
Department of Clinical Neurosciences, Centre for Clinical Brain Sciences, University of Edinburgh, Royal Infirmary of Edinburgh, UK
Parkinsonism Relat Disord 17:313-20. 2011..In this study we use these tools to describe the reported efficacy of dopamine agonists in animal models of PD.
- Dopamine modulates excitability of spiny neurons in the avian basal gangliaLong Ding
Department of Zoology, University of Washington, Seattle, Washington 98195 6115, USA
J Neurosci 22:5210-8. 2002..The diversity of DA actions enables the DA system to fine-tune the dynamics of the song system and allows flexible control over song learning and production...
- Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literatureStephane Thobois
Hopital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France
Clin Ther 28:1-12. 2006..However, the equivalence of doses of dopamine receptor agonists before and after switching drugs remains empirical because few clinical trials have addressed this issue...
- Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925Ariel Graff-Guerrero
PET Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada
Int J Neuropsychopharmacol 13:273-87. 2010..Thus, [11C](+)-PHNO seems a suitable PET radiotracer to estimate D3 receptor occupancy in humans...
- Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysisWilliam L Baker
School of Pharmacy, University of Connecticut, CT, USA
Parkinsonism Relat Disord 15:287-94. 2009Our objective was to perform a meta-analysis of randomized controlled trials of dopamine agonists (DA) as monotherapy as well as adjunctive therapy for the early treatment of Parkinson's disease (PD)...
- Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulationStacy A Castner
Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
J Neurosci 24:1446-50. 2004....
- The risky business of dopamine agonists in Parkinson disease and impulse control disordersDaniel O Claassen
Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
Behav Neurosci 125:492-500. 2011..disease (PD), impulse control disorder (ICD) can result from dopaminergic medication use, particularly dopamine agonists (DAA)...
- Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascadeTakeshi Kihara
Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
J Neurosci Res 70:274-82. 2002....
- Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysisMohamed A F M Youssef
Department of Obstetrics and Gynaecology, Cairo University, Cairo, Egypt
Hum Reprod Update 16:459-66. 2010Recently, dopamine agonists were proposed as a prophylactic treatment for ovarian hyperstimulation syndrome (OHSS) in women at high risk in IVF/ICSI treatment cycles.
- Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's diseaseFrancesca Romana Pezzella
Department of Neurological Sciences, La Sapienza University, Rome, Italy
Mov Disord 20:77-81. 2005..study showed a significant correlation between HHD and a previous history of mood disorders, and the use of dopamine agonists, either in monotherapy or in combination...
- Drug-induced deactivation of inhibitory networks predicts pathological gambling in PDT van Eimeren
Division of Brain, Imaging and Behaviour Systems Neuroscience, BIB SN, Toronto Western Research Institute, University of Toronto, Canada
Neurology 75:1711-6. 2010Some patients with Parkinson disease (PD) develop pathological gambling when treated with dopamine agonists (DAs)...
- Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and managementSean S O'Sullivan
Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, London, England
CNS Drugs 23:157-70. 2009..considered the most potent trigger for DDS in Parkinson's disease, but subcutaneous apomorphine and oral dopamine agonists may also be responsible...
- Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formationH Y Wang
Department of Pharmacology, Medical College of Pennsylvania, Philadelphia 19129, USA
Mol Pharmacol 48:988-94. 1995..The data provide evidence to suggest that in addition to coupling to Gs/adenylyl cyclase, D1-like dopamine sites that couple to Gq may mediate dopamine-stimulated formation of inositol phosphates in the rat striatum...
- Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time taskMarie Astrid Pezze
Department of Experimental Psychology, University of Cambridge, Cambridge, UK
Neuropsychopharmacology 32:273-83. 2007..The data are discussed in terms of the different functions of NAC dopamine receptors in the processing of information from its different cortico-limbic inputs...
- Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonistsSteven P Presgraves
Molecular and Cellular Biology Graduate Group, Arizona State University, Tempe, AZ, USA
Neurotox Res 5:579-98. 2004..Further characterization of the neuroprotective effects of DA agonists in this model system can provide unique information about DA receptor dependent and independent mechanisms of neuroprotection...
- Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanismsKuei Y Tseng
Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York 12208, USA
J Neurosci 24:5131-9. 2004..Thus, the modulatory actions of D1 and D2 receptors on PFC pyramidal cell excitability are mediated by multiple intracellular mechanisms and by activation of GABA(A) receptors, depending on the glutamate receptor subtypes involved...
- Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysisOlaf M Dekkers
Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
J Clin Endocrinol Metab 95:43-51. 2010b>Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprolactinemia. However, the optimal treatment strategy and treatment duration is not clear in all details.
- Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patientsJ Kreutzer
Department of Neurosurgery, University of Erlangen Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
Eur J Endocrinol 158:11-8. 2008Medical therapy with dopamine agonists (DA) is the primary treatment of choice in most patients with prolactinomas. 'Classical' surgical indications are intolerance or lack of efficiency of DA therapy...
- A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegalyShlomo Melmed
Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
J Clin Endocrinol Metab 90:4405-10. 2005....
- The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgeryRosario Pivonello
Department of Molecular and Clinical, Endocrinology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
J Clin Endocrinol Metab 94:223-30. 2009The role of dopamine agonists in the treatment of Cushing's disease (CD) has been previously debated.
- Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trialWerner H Poewe
Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
Lancet Neurol 6:513-20. 2007....
- Dopamine modulation of GABA tonic conductance in striatal output neuronsMegan J Janssen
Department of Physiology and Biophysics, Georgetown University School of Medicine, Washington, DC 20007, USA
J Neurosci 29:5116-26. 2009..Our results suggest that distinct phosphorylation of beta3-subunits may cause larger tonic current in D2+ striatopallidal MSNs, and proper intracellular conditions can reveal tonic current in D1+ cells...
- Dopamine agonist increases risk taking but blunts reward-related brain activityJordi Riba
Department of Neuropsychology, University of Magdeburg, Magdeburg, Germany
PLoS ONE 3:e2479. 2008....
- Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptorsJulie A Przybyla
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA
Eur Neuropsychopharmacol 19:138-46. 2009..These findings demonstrate a reversed stereoselectivity for the enantiomers of DOX at D(1) and alpha(2C) receptors and have implications for the therapeutic utility of doxanthrine...
- Burning mouth syndrome responsive to pramipexolJ Stuginski-Barbosa
The Department of Neurology, School of Medicine at Ribeirao Preto, Ribeirao Preto, SP, Brazil
J Headache Pain 9:43-5. 2008..We discuss potential pathophysiological implications of our findings...
- Three cases of delusional parasitosis caused by dopamine agonistsS Flann
Department of Dermatology, Orpington Hospital, Orpington, Kent, UK
Clin Exp Dermatol 35:740-2. 2010We report three cases of delusional parasitosis (DP) in patients with well-established Parkinson's disease, all of whom were taking dopamine agonists. In all three cases, the DP resolved rapidly when the drug was withdrawn.
- Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptomVirginie Czernecki
Center d Investigation Clinique, Federation de Neurologie, INSERM Unit 679, Paris, France
Mov Disord 23:964-9. 2008....
- Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damageJu Hee Lim
College of Pharmacy and Research Institute of Drug Development, Chonnam National University, 300 Yongbong Dong, Buk Gu, Gwangju 500 757, South Korea
Pharmacol Res 57:325-31. 2008..Taken together, we investigate the novel cytoprotective effect of bromocriptine involving PI3K- and Nrf2-mediated upregulation of the antioxidant enzyme NQO1...
- Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trialsJaime Kulisevsky
Unit of Movement Disorders, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Drug Saf 33:147-61. 2010b>Dopamine agonists have a well established role in the treatment of Parkinson's disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication.
- Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's diseaseDirk Deleu
College of Medicine, Sultan Qaboos University, PO Box 35, Al Khod, Sultanate of Oman
Clin Pharmacokinet 41:261-309. 2002..Drugs for which there is at least some evidence for neuroprotective effect are certain dopamine agonists, amantadine and MAO-B inhibitors (selegiline)...
- Investigation of D₂ receptor-agonist interactions using a combination of pharmacophore and receptor homology modelingMarcus Malo
Department of Chemistry, Medicinal Chemistry, University of Gothenburg, 41296 Goteborg, Sweden
ChemMedChem 7:471-82, 338. 2012..The strategy has the potential to identify weaknesses in the individual models and thereby provides an opportunity to improve the discriminating predictivity of both pharmacophore searches and structure-based virtual screens...
- Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's diseaseJohn D McCorvy
Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy and Integrative Neuroscience Program, Purdue University, West Lafayette, IN 47907, USA
Psychopharmacology (Berl) 222:81-7. 2012..Recently, we discovered doxanthrine (DOX), an oxygen bioisostere of DHX that has even greater selectivity for the D₁ dopamine receptor...
- Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's diseaseRobert B McCall
Pfizer, Inc, Kalamazoo, MI 49007, USA
J Pharmacol Exp Ther 314:1248-56. 2005..In summary, sumanirole is the first published selective D(2) receptor agonist. The compound has activity in animal models of dopamine hypofunction and has a high level of efficacy in animal models of Parkinson's disease...
- A novel dopamine agonist for the transdermal treatment of Parkinson's diseasePeter Jenner
Neurodegenerative Diseases Research Centre, Guy s, King s and St Thomas School of Biomedical Sciences, King s College, London, United Kingdom
Neurology 65:S3-5. 2005..The pharmacologic properties of rotigotine suggest that it has the characteristics necessary to form the basis of a transdermal treatment for the control of motor symptoms of PD...
- Tremor and dopamine agonistsRodger J Elble
Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL 62794 9643, USA
Neurology 58:S57-62. 2002..Comparable improvement is achieved with the dopamine agonists. Dopamine agonists are particularly well suited for patients with newly diagnosed tremor-predominant disease ..
- Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brainGráinne C O'Keeffe
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
Cell Cycle 8:2888-94. 2009..This result has implications for the use of dopaminergic therapies in PD and in the development of such therapies focusing on upregulating SVZ neurogenesis...
- Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonistsMuriel Babey
Department of Neurosurgery, University of Berne, Inselspital, 3010, Berne, Switzerland
Pituitary 14:222-30. 2011..5 months. Patients with small prolactinomas can safely consider pituitary surgery in a specialized centre with good chance of long-term remission as an alternative to long-term DA therapy...
- Practical considerations in the use of apomorphine injectableAnnette Bowron
Jubilee Day Hospital, North Tyneside General Hospital, Tyne and Wear, United Kingdom
Neurology 62:S32-6. 2004....
- Effects of acute and chronic apomorphine on sex behavior and copulation-induced neural activation in the male ratJocelien D A Olivier
Department of Anatomy, UMC St Radboud, University of Nijmegen, The Netherlands
Eur J Pharmacol 576:61-76. 2007....
- The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidenceChristian A Heidbreder
Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, 37135 Verona, Italy
Brain Res Brain Res Rev 49:77-105. 2005..Provided these results can be extrapolated to human drug addicts, they suggest that selective DA D3 receptor antagonists may prove effective as potential pharmacotherapeutic agents to manage drug dependence and addiction...
- Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptorNuska Tschammer
Department of Chemistry and Pharmacy, Friedrich Alexander University, Erlangen, Germany
Mol Pharmacol 79:575-85. 2011..Overall, the residue His393(6.55) and proximate molecular substructures of receptor ligands were identified to be crucial for multidimensional ligand efficacy...
- The time course of dopamine transmission in the ventral tegmental areaChristopher P Ford
Vollum Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
J Neurosci 29:13344-52. 2009..Thus, dopamine transmission in the midbrain is more localized then previously proposed...
- Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndromeSergio Reis Soares
Instituto Valenciano de Infertilidad, IVI Lisboa Av Infante Dom Henrique, 333 H, 1800 282 Lisbon, Portugal
Hum Reprod Update 14:321-33. 2008..Ovarian hyperstimulation syndrome (OHSS) typically occurs when ovaries are primed with FSH/LH and subsequently exposed to hCG. The ultimate pathophysiological step underlying this clinical picture is increased vascular permeability (VP)...
- Efficacy and safety of dopamine agonists in traumatic brain injury: a systematic review of randomized controlled trialsAnne Julie Frenette
Department of Pharmacy, Hopital du Sacre Coeur de Montreal, Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada
J Neurotrauma 29:1-18. 2012In the intensive care unit, dopamine agonists (DA) have been used in traumatic brain injury (TBI) patients to augment or accelerate cognitive recovery and rehabilitation...
- Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetesRichard Scranton
Veroscience LLC, 1334 Main Road, Tiverton, RI 02878, USA
Expert Opin Pharmacother 11:269-79. 2010..The quick-release formulation of bromocriptine (bromocriptine-QR; Cycloset) represents such a therapy...
- Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptorSarah L Payne
School of Animal and Microbial Sciences, University of Reading, UK
J Neurochem 82:1106-17. 2002....
- Physiology and pathology of ovarian hyperstimulation syndromeRaul Gomez
Instituto Universitario IVI, Universidad de Valencia, Valencia, Spain
Semin Reprod Med 28:448-57. 2010..Pharmaco-prevention through dopamine agonists is effective only in nonpregnant high-risk OHSS women...
- Clinical practice. ProlactinomaJanet A Schlechte
Department of Internal Medicine, University of Iowa, Iowa City, USA
N Engl J Med 349:2035-41. 2003
- Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonistsLisa M Neff
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tufts New England Medical Center, Boston, MA 02111, USA
Pituitary 10:81-6. 2007Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients ..
- Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivoRajesh Narendran
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York 10032, USA
Synapse 60:485-95. 2006..This property might contribute to its higher vulnerability to endogenous DA compared to [11C]raclopride and [11C]NPA...
- The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cellsJ E de Leeuw van Weenen
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
Biochem Pharmacol 79:1827-36. 2010..We suggest that treatment with bromocriptine promotes beta cells rest, thereby preventing long-lasting hypersecretion of insulin and subsequent beta cell failure...
- Ovarian hyperstimulation syndrome: pathophysiology and preventionCarolina O Nastri
Departamento de Ginecologia e Obstetrícia da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo DGO HC FMRP USP, Avenida dos Bandeirantes 3900, 8 masculine Andar, Ribeirao Preto, Sao Paulo, Brazil, CEP 14049 900
J Assist Reprod Genet 27:121-8. 2010..To review and discuss the pathophysiology and prevention strategies for ovarian hyperstimulation syndrome (OHSS), which is a condition that may occur in up to 20% of the high risk women submitted to assisted reproductive technology cycles...
- Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatmentRaul Gomez
Fundacion IVI, Institituto Universitario IVI Fundación Investigación Clinico de Valencia INCLIVA, 46015 Valencia, Spain
J Clin Endocrinol Metab 96:2484-92. 2011..Deregulation of the VEGF/VEGF receptor (VEGFR)-2 pathway leading to increased risk of ovarian hyperstimulation syndrome has been described in the ovary of patients suffering from polycystic ovarian syndrome (PCOS)...
- Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion tableKatherine Grosset
Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
Mov Disord 19:1370-4. 2004Of 99 patients on ergot-derived dopamine agonists informed about possible long-term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%...
- Neural cell adhesion molecule modulates dopaminergic signaling and behavior by regulating dopamine D2 receptor internalizationMei fang Xiao
Zentrum für Molekulare Neurobiologie, Universitatsklinikum Hamburg Eppendorf, D 20246 Hamburg, Germany
J Neurosci 29:14752-63. 2009....
- Efficacy and safety of dopamine agonists in restless legs syndromeMagdolna Hornyak
Interdisciplinary Pain Centre, University Medical Centre, Breisacher Strasse 64, 79106 Freiburg, Germany
Sleep Med 13:228-36. 2012..This article is an overview of a comprehensive Cochrane meta-analysis on the efficacy and safety of dopamine agonists (DAs), the first-line treatment of RLS.
- Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?Sophie Vallette
Department of Endocrinology, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Sherbrooke East, Montreal, QC, H2L 4M1, Canada
Expert Rev Cardiovasc Ther 8:49-54. 2010b>Dopamine agonists (DAs) are the first-line therapy for the treatment of hyperprolactinemia, with cabergoline, an ergot-derived selective D(2)-receptor agonist, being the preferred and most widely used drug...
- Cognitive status of patients with Parkinson's disease and pathological gamblingChiara Siri
Parkinson Institute, Istituti Clinici di Perfezionamento, 20126, Milan, Italy
J Neurol 257:247-52. 2010..In conclusion the occurrence of PG in our cohort of patients with PD was associated with preserved executive functions...
- Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgiaAndrew J Holman
Pacific Rheumatology Research, 4300 Talbot Road South, Suite 101, Renton, WA, 98055, USA
J Gambl Stud 25:425-31. 2009Compulsivity has been associated with use of dopamine agonists used to treat Parkinson's disease (PD). Increasing use of these agents to treat fibromyalgia (FM) raises concern for this unexpected toxicity in a new group of patients...
- Pregnancy outcome after cabergoline treatment in early weeks of gestationElena Ricci
Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62 20157, Milan, Italy
Reprod Toxicol 16:791-3. 2002..The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline...
- Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case seriesDavid A Gallagher
Department of Clinical Neurosciences, Royal Free and University College Medical School, London, United Kingdom
Mov Disord 22:1757-63. 2007..cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS)...
- Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependenceKaren D Ersche
University of Cambridge, Behavioural and Clinical Neuroscience Institute, Department of Psychiatry, Cambridge, England
Arch Gen Psychiatry 67:632-44. 2010..We hypothesized that dopamine-related targets are relevant for treatment of stimulant dependence, and there will likely be individual differences in response to dopaminergic challenges...
- Dopamine agonists and sleepiness in PD: review of the literature and personal findingsRaffaele Manni
Unit of Sleep Medicine and Epilepsy, IRCCS C Mondino Institute of Neurology, Pavia, Italy
Sleep Med 5:189-93. 2004This study is aimed at evaluating daytime sleepiness in a series of Parkinson's disease (PD) patients chronically treated with dopamine agonists (DAs) alone or in combination with L-Dopa.
- Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesiaMark Stacy
Division of Neurology, Duke University Medical Center, Durham, North Carolina 27705, USA
Clin Neuropharmacol 31:51-6. 2008The treatment of Parkinson disease (PD) involves pharmacological treatment, often with levodopa or dopamine agonists, to restore the dopaminergic deficit associated with parkinsonian symptoms...
- Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteersM A Mehta
Department of Psychiatry, University of Cambridge, School of Clinical Medicine, Addenbrooke s Hospital, UK
Psychopharmacology (Berl) 159:10-20. 2001..Studies in humans of cognitive effects of dopaminergic drugs have largely focused on tasks of working memory, with a few studies also examining executive function...
- Prolactinomas in children and adolescents. Clinical presentation and long-term follow-upA Colao
Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II di Napoli, Naples, Italy
J Clin Endocrinol Metab 83:2777-80. 1998..In conclusion, the medical treatment with dopaminergic compounds is effective and safe in patients with prolactinoma with onset in childhood, allowing preservation of the anterior pituitary function...
- Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?Thilo van Eimeren
Division of Brain, Imaging and Behaviour Systems Neuroscience, BIB SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada
Neuropsychopharmacology 34:2758-66. 2009..Treatment with dopamine agonists (DAs) has been associated with pathological gambling in PD patients...
- Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese womenPetra Kok
Department of Internal Medicine C4 83, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
J Clin Endocrinol Metab 91:3236-40. 2006..This study was done to establish the effect of bromocriptine treatment on circadian plasma leptin concentrations in obese humans...
- A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memorySasha E B Gibbs
Henry H Wheeler Jr Brain Imaging Center, Helen Wills Neuroscience Institute and Department of Psychology, University of California, Berkeley, 132 Barker Hall, Berkeley, CA 94720 3190, USA
Psychopharmacology (Berl) 180:644-53. 2005....
- Chemistry of the adaptive mindRoshan Cools
Department of Experimental Psychology, University of Cambridge, Downing Street, Cambridge CB2 3EB, UK
Philos Trans A Math Phys Eng Sci 362:2871-88. 2004..The work has considerable implications for the understanding of and treatment development for abnormalities such as Parkinson's disease, attention deficit hyperactivity disorder and drug addiction...
- Prevalence of repetitive and reward-seeking behaviors in Parkinson diseaseV Voon
Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 1428, USA
Neurology 67:1254-7. 2006..4%. Compulsive shopping was 0.7%. Combined with our pathologic gambling data, the lifetime prevalence of these behaviors was 6.1% and increases to 13.7% in patients on dopamine agonists.
- Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studiesF Bogazzi
Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
J Endocrinol Invest 31:1119-23. 2008b>Dopamine agonists have been associated with increased risk of cardiac valve regurgitation in patients with Parkinson's disease. Whether these drugs might be harmful for patients with hyperprolactinemia is still unsettled...
- Cabergoline and the risk of valvular lesions in endocrine diseasePatrizio Lancellotti
Department of Cardiology, Centre Hospitalier Universitaire de Liege, Domaine Universitaire du Sart Tilman, University of Liege, B 4000 Liege, Belgium
Eur J Endocrinol 159:1-5. 2008..The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown...
- Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart diseaseAmmar Wakil
Michael White Diabetes Centre, Hull Royal Infirmary, Brocklehurst Building, 220 236 Anlaby Road, Hull HU3 2RW, UK
Eur J Endocrinol 159:R11-4. 2008Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease...
- Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out miceRebecca J Ralph-Williams
Alcohol and Drug Abuse Research Center, Harvard Medical School and McLean Hospital, Belmont, Massachusetts 02478, USA
J Neurosci 22:9604-11. 2002..These findings emphasize that further cross-species comparisons of the pharmacology of PPI are essential to understand the relevance of rodent PPI studies to the deficits in PPI observed in patients with schizophrenia...
- Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imagingMarina Delfino
Laboratorio de Parkinsonismo Experimental, Instituto de Investigaciones Farmacologicas, CONICET, Buenos Aires, Argentina
Neuropsychopharmacology 32:1911-21. 2007..As a first step towards disclosing drug-induced brain activation in dyskinesia, we examined the effects of dopamine agonists on behavior and blood oxygenation level-dependent (BOLD) signal in the striatum and motor cortex of rats ..
- Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET studyAlan L Whone
Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
Ann Neurol 54:93-101. 2003..1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by (18)F-dopa PET...
- Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case seriesG Perugi
Department of Psychiatry, University of Pisa, Italy
Pharmacopsychiatry 34:137-41. 2001Previous studies and case observations have suggested that dopamine agonists (DAAs) such as pramipexole (PPX) and ropinirole (RPN) might be effective for major depression, but their adjunctive use in treatment-resistant bipolar II ..
- Compulsive eating and weight gain related to dopamine agonist useMelissa J Nirenberg
Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, NY 10021, USA
Mov Disord 21:524-9. 2006b>Dopamine agonists have been implicated in causing compulsive behaviors in patients with Parkinson's disease (PD). These have included gambling, hypersexuality, hobbyism, and other repetitive, purposeless behaviors ("punding")...
- Clinical features associated with impulse control disorders in Parkinson diseaseGregory Pontone
Department of Psychiatry and Behavioral Sciences, Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Neurology 67:1258-61. 2006..Subjects were participants in a longitudinal study of PD. ICDs were associated with use of dopamine agonists and depressed mood, disinhibition, irritability, and appetite disturbance.
- Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomasM Biswas
Department of Endocrinology, University Hospital of Wales, Heath Park, Cardiff, Wales, UK
Clin Endocrinol (Oxf) 63:26-31. 2005..Subjects received dopamine agonist (DA) therapy with either cabergoline or bromocriptine for a period of 2 to 3 years in the majority of cases, followed by a trial of treatment withdrawal...
- Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategyA Di Sarno
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, 80131 Naples, Italy
J Clin Endocrinol Metab 86:5256-61. 2001..Therefore, an absence of tumor shrinkage cannot be considered as end point to indicate resistance to CAB, and increasing the dose of CAB higher than 3 mg/wk does not seem to be helpful in controlling PRL hypersecretion...
- Prevalence of problem and pathological gambling in Parkinson's diseaseDavid Crockford
Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada, T2N 2T9
J Gambl Stud 24:411-22. 2008Pathological gambling (PG) has been identified in patients with Parkinson's disease (PD) treated with dopamine agonists suggesting that dysregulation of brain dopaminergic activity may contribute to the development of gambling problems...
- Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are requiredM Kars
Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
Eur J Endocrinol 159:363-7. 2008..Parkinson's disease with cabergoline has raised concerns about the safety of treatment with ergot-derived dopamine agonists in patients with endocrine diseases, especially prolactinoma...
- Prolactinomas and pregnancyMarcello Delano Bronstein
Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of S Paulo Medical School, Av 9 de Julho 3858, 01406 100, S Paulo, SP, Brazil
Pituitary 8:31-8. 2005..Since then, dopamine agonists (DA) have been increasingly used as the first-choice treatment of prolactinomas, with surgery being reserved ..
- Dopamine agonist withdrawal syndrome in Parkinson diseaseChristina A Rabinak
Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York 10021, USA
Arch Neurol 67:58-63. 2010..To report and characterize a dopamine agonist (DA) withdrawal syndrome (DAWS) in Parkinson disease...
- Rotigotine transdermal delivery for the treatment of Parkinson's diseaseOlivier Rascol
Clinical Investigation Center and Neurosciences Institute, Department of Clinical Pharmacology, Faculty of Medicine, INSERM U 825, Toulouse, France
Expert Opin Pharmacother 10:677-91. 2009..An interesting element of this profile is constant drug delivery, which may avoid pulsatile dopaminergic stimulation, which has been postulated to be related to the development of motor complications...
- Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonistsVanessa Q Passos
Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Brazil
Neuroendocrinology 89:163-70. 2009..Prolactinomas are the most common secreting pituitary adenomas, and dopamine agonists (DA) are the first choice for their treatment. However, a subset of patients is resistant to DA...
- Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intoleranceIsabel Garcia-Tornadú
Instituto de Biologia y Medicina Experimental CONICET, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina
Endocrinology 151:1441-50. 2010..Pancreatic D2Rs inhibit glucose-stimulated insulin release. Lack of dopaminergic inhibition throughout development may exert a gradual deteriorating effect on insulin homeostasis, so that eventually glucose intolerance develops...
- Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesiasM A Delfino
Laboratorio de Parkinson Experimental, ININFA CONICET, Junin 956, 5 degrees piso, C1113AAD Buenos Aires, Argentina
Behav Brain Res 152:297-306. 2004....
- Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonistsKarina L Bienfait
Department of Psychiatry, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 671 Hoes Lane, Piscataway, NJ 08854, USA
J Clin Neurosci 17:539-40. 2010..We postulate this to be related to an overstimulation of mesolimbic dopamine receptors responsible for reward-seeking behaviors. Further research is needed to examine impulsive cigarette smoking in PD...
- COCAINE INDUCED OPIOID, DOPAMINE AND BEHAVIORAL CHANGESELLEN UNTERWALD; Fiscal Year: 2002..The potential outcome of these studies may be the information necessary for the development of more selective pharmacotherapeutic agents for the chronic management of cocaine addiction. ..
- Extrastriatal functions of dopamineTHOMAS N WICHMANN; Fiscal Year: 2010..If significant dopaminergic effects are seen in the subthalamic nucleus, it may emerge as a new target for highly specific local dopamine replacement therapies for parkinsonian patients. ..
- ULTRASTRUCTURE OF MESOLIMBIC TRANSMITTER INTERACTIONSVirginia M Pickel; Fiscal Year: 2010....
- Subtype Specific Agonists for D1-D5 Dopamine ReceptorsWilliam Goddard; Fiscal Year: 2007..receptors can induce side effects similar to those resulting from dopamine depletion, and high doses of dopamine agonists can cause psychoses...
- Role of Endocannabinoids in Levodopa-Induced DyskinesiasAndrea Giuffrida; Fiscal Year: 2007..In conclusion, our study will elucidate the role of the endocannabinoid system in levodopa-associated dyskinesias and provide a rational to develop new treatments that act via the endocannabinoid system. ..
- Developmental Psychopharmacology of AntipsychoticsJENNY WILEY; Fiscal Year: 2007..to challenges with dopaminergic agents in later life such that animals are more sensitive to the effects of dopamine agonists and less sensitive to those of dopamine antagonists...
- DEVELOPMENT OF POTENTIALLY SELECTIVE DOPAMINE AGONISTSDavid Nichols; Fiscal Year: 2000....
- Medications for Comorbid Cocaine and Alcohol DependenceRolley Johnson; Fiscal Year: 2002..Over the past decade, medications including dopamine agonists, antagonists, tricyclic antidepressants, selective serotonin reuptake inhibitors, opiate mixed agonist-..
- The neurogenic potential of cholinergic activation in AD.ELIZABETH ADAMS ECKMAN; Fiscal Year: 2010..If successful, these studies may yield novel insights into potential treatment strategies and will also increase our understanding of the factors capable of regulating new cell formation in the adult brain. ..
- The neurogenic potential of cholinergic activation in AD.Elizabeth Eckman; Fiscal Year: 2009..If successful, these studies may yield novel insights into potential treatment strategies and will also increase our understanding of the factors capable of regulating new cell formation in the adult brain. ..
- BRAIN DOPAMINE REGULATION OF MALE SEX BEHAVIOR IN RATSElaine Hull; Fiscal Year: 1990....
- NEUROPHARMACOLOGY OF ETHANOL REINFORCEMENTGeorge Koob; Fiscal Year: 1991..shown that low doses of ethanol can release dopamine in the region of the nucleus accumbens and that dopamine agonists appear to reduce ethanol preference without decreasing water intake...
- DEVELOPMENT OF POTENTIALLY SELECTIVE DOPAMINE AGONISTSDavid Nichols; Fiscal Year: 2007..Our work will generate molecular probes that should help to increase our understanding of these pathways, and may also provide new therapies for disorders such as Parkinson's disease and schizophrenia. ..
- A Genetic Test for Drug-Induced Dyskinesia Risk DeterminationAbraham Kovoor; Fiscal Year: 2007..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. ..
- A Genetic Test for Drug-Induced Dyskinesia Risk DeterminationAbraham Kovoor; Fiscal Year: 2007..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. ..
- STARTLE GATING AND LOCOMOTION IN D2-FAMILY KNOCKOUT MICEMark Geyer; Fiscal Year: 2004..habituation, and prepulse inhibition; (3) characterize the effects of amphetamine and selected direct dopamine agonists on the same measures; (4) characterize the effects of amphetamine and selected direct dopamine agonists on ..
- Prolactin as a Growth Factor in Breast CancerNira Ben Jonathan; Fiscal Year: 2010..Aim 4: To establish mixed-cultures of fully differentiated LS14 adipocytes and BCC and examine whether dopamine agonists sensitize LS14/BCC tumors in athymic mice to anticancer drugs...
- New Dopamine D1 Agonists as PET Imaging AgentsONOFRE DEJESUS; Fiscal Year: 2007..Because the high Affinity state is the physiologically functional state, dopamine agonists are preferred as PET imaging agents since they can discriminate between high and low affinity states...
- SELF-INJURIOUS BEHAVIOR: MOLECULAR MARKERSDARRAGH DEVINE; Fiscal Year: 2002....
- PRO LEU GLY NH2 AMD DOPAMINE RECEPTOR MODULATION STUDYRodney Johnson; Fiscal Year: 1999..1) the ability of Gs and Gi antisense oligonucleotides to modulate rotational behavior induced by dopamine agonists in 6-hydroxydopamine lesioned rats in the presence and absence of PLG analogues; (2) the G protein levels ..
- Cocaine effects on neuronsJohn T Williams; Fiscal Year: 2010..PUBLIC HEALTH RELEVANCE: Dopamine agonists and antagonists are used clinically for the treatment of a number of diseases pointing out the importance of ..